Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 18;25(1):74.
doi: 10.1186/s12874-024-02410-3.

Sample size recalculation based on the overall success rate in a randomized test-treatment trial with restricting randomization to discordant pairs

Affiliations

Sample size recalculation based on the overall success rate in a randomized test-treatment trial with restricting randomization to discordant pairs

Caroline Elzner et al. BMC Med Res Methodol. .

Abstract

Background: Randomized test-treatment studies are performed to evaluate the clinical effectiveness of diagnostic tests by assessing patient-relevant outcomes. The assumptions for a sample size calculation for such studies are often uncertain.

Methods: An adaptive design with a blinded sample size recalculation based on the overall success rate in a randomized test-treatment trial with restricting randomization to discordant pairs is proposed and evaluated by a simulation study. The results of the adaptive design are compared to those of the fixed design.

Results: The empirical type I error rate is sufficiently controlled in the adaptive design as well as in the fixed design and the estimates are unbiased. The adaptive design achieves the desired theoretical power, whereas the fixed design tends to be over- or under-powered.

Conclusions: It may be advisable to consider blinded recalculation of sample size in a randomized test-treatment study with restriction of randomization to discordant pairs in order to improve the conduct of the study. However, there are a number of study-related limitations that affect the implementation of the method which need to be considered.

Keywords: Adaptive design; Diagnostic test; Discordance design; Overall success rate; Sample size recalculation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Results for the empirical type I error vs. the difference between true and initially assumed overall success rate for the 144 scenarios (πϵ0.1,0.2,0.3,ωϵ0.05,0.1,0.15,SeA,SpAϵ0.8,0.9,SeB,SpBϵ0.6,0.7,0.8) using minimal discordant rate, stratified by the prevalence. The empirical type I error rates for the fixed design and the adaptive design containing a re-estimation of the overall success rate are compared to each other. The black dotted line marks the desired theoretical type I error rate of 5% and the black solid lines mark the respective 95% prediction interval based on the Monte Carlo standard error in the simulation
Fig. 2
Fig. 2
Results for the empirical power vs. the difference between true and initially assumed overall success rate for the 144 scenarios (πϵ0.1,0.2,0.3,ωϵ0.05,0.1,0.15,SeA,SpAϵ0.8,0.9,SeB,SpBϵ0.6,0.7,0.8) using minimal discordant rate, stratified by the prevalence. The empirical power in the fixed design is compared to the adaptive design containing a re-estimation of the overall success rate. The black dotted line marks the desired theoretical power of 80%
Fig. 3
Fig. 3
Results of the calculated initial, adjusted and true sample sizes of discordant cases vs. the difference between true and initially assumed overall success rate for the 144 scenarios (πϵ0.1,0.2,0.3,ωϵ0.05,0.1,0.15,SeA,SpAϵ0.8,0.9,SeB,SpBϵ0.6,0.7,0.8) using minimal discordant rate (based on data generated under the null hypothesis), stratified by the prevalence

Similar articles

References

    1. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Evaluation of Diagnostic Agents. European Medicines Agency. 2009. Available from: https://www.ema.europa.eu/en/document. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-cl....
    1. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford university press; 2003.
    1. Rodger M, Ramsay T, Fergusson D. Diagnostic randomized controlled trials: the final frontier. Trials. 2012;13(1):1–7. - PMC - PubMed
    1. Schünemann AHJ, Oxman AD, Brozek J, Glasziou P, Vist GE, Jr JWW, et al. GRADE : grading of quality of evidence and strength of recommendations for diagnostic tests and strategies. Br Med J. 2008;336(may). - PMC - PubMed
    1. Lijmer JG, Bossuyt PMM. Various randomized designs can be used to evaluate medical tests. J Clin Epidemiol. 2009Apr;62(4):364–73. - PubMed

LinkOut - more resources